PharmaEssentia Future Growth

Future criteria checks 5/6

PharmaEssentia is forecast to grow earnings and revenue by 86.2% and 41.5% per annum respectively. EPS is expected to grow by 85.4% per annum. Return on equity is forecast to be 18.1% in 3 years.

Key information

86.2%

Earnings growth rate

85.4%

EPS growth rate

Biotechs earnings growth	35.3%
Revenue growth rate	41.5%
Future return on equity	18.1%
Analyst coverage	Low
Last updated	23 Sep 2024

Recent future growth updates

No updates

Recent updates

Earnings and Revenue Growth Forecasts

BDL:261280523 - Analysts future estimates and past financials data (TWD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	20,526	N/A	N/A	N/A	2
12/31/2025	14,840	5,930	3,017	5,042	4
12/31/2024	9,649	3,282	1,012	2,752	4
6/30/2024	6,913	1,325	-138	897	N/A
3/31/2024	5,871	442	-1,426	-274	N/A
12/31/2023	5,106	-624	-2,033	-706	N/A
9/30/2023	4,300	-890	-1,867	-1,113	N/A
6/30/2023	3,805	-1,498	-2,318	-1,549	N/A
3/31/2023	3,518	-1,569	-2,063	-1,436	N/A
12/31/2022	2,882	-1,375	-1,826	-1,505	N/A
9/30/2022	2,420	-2,111	-1,822	-1,572	N/A
6/30/2022	1,702	-2,403	-2,160	-2,068	N/A
3/31/2022	811	-2,669	-2,597	-2,531	N/A
12/31/2021	657	-2,811	-2,560	-2,462	N/A
9/30/2021	569	-2,756	-2,814	-2,657	N/A
6/30/2021	610	-2,673	-2,643	-2,440	N/A
3/31/2021	654	-2,340	-2,215	-2,019	N/A
12/31/2020	557	-1,948	-1,663	-1,455	N/A
9/30/2020	464	-1,204	-1,266	-1,020	N/A
6/30/2020	332	-862	-1,053	-845	N/A
3/31/2020	271	-856	-1,077	-844	N/A
12/31/2019	306	-843	-1,151	-945	N/A
9/30/2019	130	-1,113	-978	-836	N/A
6/30/2019	129	-1,080	-1,099	-919	N/A
3/31/2019	61	-1,086	-1,067	-899	N/A
12/31/2018	26	-1,040	-978	-827	N/A
9/30/2018	4	-930	-940	-823	N/A
6/30/2018	4	-882	-820	-749	N/A
3/31/2018	4	-878	N/A	-755	N/A
12/31/2017	4	-872	N/A	-790	N/A
9/30/2017	4	-862	N/A	-750	N/A
6/30/2017	5	-898	N/A	-762	N/A
3/31/2017	6	-904	N/A	-696	N/A
12/31/2016	5	-845	N/A	-657	N/A
9/30/2016	7	-892	N/A	-685	N/A
6/30/2016	9	-865	N/A	-628	N/A
3/31/2016	11	-870	N/A	-579	N/A
12/31/2015	12	-853	N/A	-527	N/A
9/30/2015	9	-819	N/A	-556	N/A
6/30/2015	9	-804	N/A	-567	N/A
3/31/2015	9	-796	N/A	-601	N/A
12/31/2014	13	-853	N/A	-599	N/A
9/30/2014	17	-812	N/A	-470	N/A
6/30/2014	19	-833	N/A	-448	N/A
3/31/2014	46	-713	N/A	-367	N/A
12/31/2013	72	-593	N/A	-285	N/A
9/30/2013	81	-449	N/A	-240	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 261280523's forecast earnings growth (86.2% per year) is above the savings rate (2.4%).

Earnings vs Market: 261280523's earnings (86.2% per year) are forecast to grow faster than the Luxembourg market (14% per year).

High Growth Earnings: 261280523's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 261280523's revenue (41.5% per year) is forecast to grow faster than the Luxembourg market (5.1% per year).

High Growth Revenue: 261280523's revenue (41.5% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 261280523's Return on Equity is forecast to be low in 3 years time (18.1%).

PharmaEssentia Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Recent updates

PharmaEssentia Corporation Announces Taiwan MOHW Approves IND Application of Phase I Clinical Trial of Sequential Treatment of P1801 Following P1101 in Patients with Advanced Solid Tumors in Principle

PharmaEssentia Corporation to Report Q2, 2024 Results on Aug 13, 2024

PharmaEssentia Corporation Announces Update on its IND Application of Phase I Clinical Trial of Sequential Treatment of P1801 Following P1101 in Patients with Advanced Solid Tumors

Pharmaessentia Corporation Announces Appointments to Board of Directors

Pharmaessentia Corporation Announces Appointments to Board of Directors

PharmaEssentia Corporation Provides an Update on Submission of P1101 PhaseIII Clinical Study Protocol for Pre-fibrotic/Early PMFor Overt PMF at Low to Intermediate-1 Risk to China NMPA

PharmaEssentia Corporation to Report Q1, 2024 Results on May 13, 2024

PharmaEssentia Corp. Submits Phase III Clinical Study Protocol of P1101 for Pre-fibrotic/ Early PMF or OvertPMF at Low to Intermediate-1 Risk to China NMPA

PharmaEssentia Corp. Announces Submission of Marketing Authorization Application of BESREMi (Ropeginterferon alfa-2B) for PV in Colombia

PharmaEssentia Corporation announced a financing transaction

PharmaEssentia Corporation Updates on IND Application of Phase I Clinical Trial of Sequential Treatment of P1801 Following P1101 in Patients with Advanced Solid Tumors to TFDA

PharmaEssentia Corporation Submits IND Application of Phase I Clinical Trial of P2203 to Taiwan Food and Drug Administration

PharmaEssentia Corporation, Annual General Meeting, May 27, 2024

PharmaEssentia Corporation, Annual General Meeting, May 27, 2024

PharmaEssentia Corporation Submits Phase III Clinical Study Protocol of P1101 for Pre-Fibrotic/Early PMF or Overt PMF At Low to Intermediate-1 Risk to U.S. FDA

PharmaEssentia Corporation Announces Enrollment Completion of Phase III Clinical Trial of Ropeginterferon alfa-2b for Essential Thrombocythemia

Pharmaessentia Corp. Announces 52-Week Result of the Phase II Clinical Trial of Ropeginterferon Alfa-2B (P1101) for the Treatment of PV in China

PharmaEssentia Corporation Receives Civil Lawsuit Decision from Middlesex Superior Court for the Commonwealth of Massachusetts

PharmaEssentia Corporation Announces Publication of New Results from A Phase 2 Clinical Study with ropeginterferon Alfa-2B (Marketed as Besremi®) for the Treatment of Patients with Polycythemia Vera (PV)

PharmaEssentia Corp. Announces Submission of New Drug Registration of BESREMi (Ropeginterferon Alfa-2b) for PV in Hong Kong

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies